Help Patients Get to Goal With Heart Failure Meds
January 2023
Questions will come up about titrating meds for heart failure with reduced ejection fraction (HFrEF) in hospitalized patients.
Less than 1% of patients are on target-dose “triple therapy” with an ACEI, ARB, or sacubitril/valsartan (Entresto)...an evidence-based beta-blocker (carvedilol, etc)...and an aldosterone antagonist.
Even fewer get the latest guideline-recommended “quad therapy” for HFrEF...by adding an SGLT2 inhibitor (dapagliflozin, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote